Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Mammographic Breast Density (MBD) Reduction in Premenopausal Women: Goserelin achieved a 2.7% reduction in MBD among premenopausal women without a breast cancer history, with MBD returning to baseline post-treatment. Comparatively, tamoxifen and leuprolide acetate showed higher MBD reductions (13.4% and 8.9%, respectively), while nonhormonal interventions like vitamin D and isoflavones showed no reduction.
• Uterine Fibroids Treatment in Premenopausal Women: Goserelin was less effective in reducing abnormal uterine bleeding than oral progestogens (dienogest and desogestrel), with no significant effect on fibroid size observed.
• Safety in Prostate Cancer Treatment: Goserelin, compared to gonadotropin-releasing hormone (GnRH) antagonists (degarelix and relugolix), demonstrated a higher incidence of adverse cardiovascular events, with pooled risk ratios significantly favoring GnRH antagonists for lower cardiovascular events (0.57), cardiovascular death (0.49), and all-cause mortality (0.48).
• Uterine Fibroids: Goserelin was associated with vasomotor symptoms, such as hot flashes, in 55% of users, while oral progestogens (dienogest and desogestrel) did not show such adverse events.
• There is no population types or subgroups information available in the reviewed studies.